Search Results

You are looking at 1 - 10 of 165 items for :

  • "cardiovascular diseases" x
Clear All
Free access

Amanda J Rickard and Morag J Young

induced by macrophage activation are central to the pathogenesis of disease states such as cardiovascular disease ( Yan & Hansson 2007 ), cancer ( Coussens & Werb 2002 ) and metabolic syndrome ( Zeyda & Stulnig 2007 ). Furthermore, emerging evidence

Free access

Ana Luísa Neves, João Coelho, Luciana Couto, Adelino Leite-Moreira and Roberto Roncon-Albuquerque Jr

junctions. The absence of Cd14 in ob/ob mutant mice provokes the same metabolic and inflammatory effects of antibiotics Human studies   Wiedermann et al . (1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease

Restricted access

Yousheng Xu, Yongshun Wang, Jingjin Liu, Wei Cao, Lili Li, Hongwei Du, Enbo Zhan, Ruoxi Zhang, Huimin Liu, Maoen Xu, Tao Chen, Yilin Qu and Bo Yu

Introduction The prevalence of overweight and obesity in the world has risen dramatically. Obesity is associated with significant metabolic disorders and may trigger severe cardiovascular diseases ( Piche et al. 2018 ). Among them

Open access

Emma J Agnew, Jessica R Ivy, Sarah J Stock and Karen E Chapman

-up studies have demonstrated adverse neurodevelopmental effects in children born preterm or exposed to multiple courses of ACT ( Asztalos et al . 2014 , Crowther et al . 2016 ). Whether ACT affects risk of cardiovascular disease in humans remains unclear

Free access

Lichun Zhou, Baohua Ma and Xiuzhen Han

Zhang L 2011 Angiotensin II receptors and drug discovery in cardiovascular disease . Drug Discovery Today 16 22 – 34 . ( doi:10.1016/j.drudis.2010.11.016 ) Demos-Davies KM Ferguson BS Cavasin MA Mahaffey JH Williams SM

Free access

Patricia M Lenhart, Stefan Broselid, Cordelia J Barrick, L M Fredrik Leeb-Lundberg and Kathleen M Caron

cardiovascular disease. Despite what is known about GPR30, there remains intense controversy regarding the trafficking and subcellular localization of GPR30, in addition to many conflicting reports regarding its downstream signaling and even ligand

Free access

Diana Vargas, Noriaki Shimokawa, Ryosuke Kaneko, Wendy Rosales, Adriana Parra, Ángela Castellanos, Noriyuki Koibuchi and Fernando Lizcano

Introduction Obesity and its associated metabolic diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular disease, are increasing in prevalence due to a combination of environmental factors and genetic variations ( van Dijk et

Free access

Mirel-Adrian Popa, Maria-Cristina Mihai, Alina Constantin, Viorel Şuică, Cătălin Ţucureanu, Raluca Costache, Felicia Antohe, Raghvendra K Dubey and Maya Simionescu

, and drop in androgen levels is associated with cardiovascular disease ( Dubey et al . 2002 ). Since MSC integration would require short-term exposure to DHT-primed MSCs, it is feasible that its beneficial actions may override its, potential, long

Free access

Jerzy-Roch Nofer

2007 Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause . Journal of the American Medical Association 297 1465 – 1477 . doi:10.1001/jama.297.13.1465 . Saintier D Khanine V Uzan B Ea HK de

Free access

Thalijn Liliana Catharina Wolters, Mihai Gheorghe Netea, Adrianus Rudolfus Marinus Maria Hermus, Johannes Willem Adriaan Smit and Romana Teodora Netea-Maier

increased GH and IGF1 levels induces a pro-inflammatory state that contributes to the development of cardiovascular diseases (CVD) in acromegaly. Few studies have assessed the direct effects of GH and/or IGF1 on cytokine production ( Renier et al . 1996